# Monthly Dosing of Atacicept in IgAN

> **NCT07020923** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vera Therapeutics, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- IgA Nephropathy (IgAN)
- Berger Disease

## Interventions

- **DRUG:** Atacicept

## Key facts

- **NCT ID:** NCT07020923
- **Lead sponsor:** Vera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020923, "Monthly Dosing of Atacicept in IgAN". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07020923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*